Literature DB >> 9521085

The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules.

P Kjellén1, U Brunsberg, J Broddefalk, B Hansen, M Vestberg, I Ivarsson, A Engström, A Svejgaard, J Kihlberg, L Fugger, R Holmdahl.   

Abstract

The Aq major histocompatibility complex (MHC) class II molecule is associated with susceptibility to murine collagen-induced arthritis (CIA), whereas the closely related H-2Ap molecule is not. To understand the molecular basis for this difference, we have analyzed the ability of H-2Aq and H-2Ap molecules (referred to as Aq and Ap) to bind and present collagen type II (CII)-derived glycosylated and non-glycosylated peptides. T cell clones specific for the immunodominant CII 256-270 peptide and restricted to both Aq and Ap molecules were identified. When these clones were incubated with CII protein and either Aq- or Ap-expressing antigen-presenting cells (APC), only Aq-expressing APC were able to induce stimulation. With the use of A(beta) transgenic mice this could be shown to be solely dependent on the MHC class II molecule itself and to be independent of other MHC- or non-MHC genes. Peptide binding studies were performed using affinity-purified MHC class II molecules. The CII 256-270 peptide bound with lower affinity to the Ap molecule than to the Aq molecule. Using a set of alanine-substituted CII 256-270 peptides, MHC class II and T cell receptor (TCR) contacts were identified. Mainly the side chains of isoleucine 260 and phenylalanine 263 were used for binding both the Aq and Ap molecule, i.e. the peptide was orientated similarly in the binding clefts. The major TCR contact amino acids were lysine 264, which can be posttranslationally modified, and glutamic acid 266, which is the only amino acid in the heterologous peptide which differs from the mouse sequence. Glycosylation at positions 264 and 270 of the CII 256-270 peptide did not change the anchor positions used for binding to the Aq or Ap molecules. The autologous form of the peptide (with aspartic acid at position 266) bound with lower affinity to the Aq molecule as compared with the heterologous peptide. The variable affinity displayed by the immunodominant CII 256-270 peptide for different MHC class II molecules, the identification of MHC and TCR contacts and the significance of glycosylation of these have important implications for the understanding of the molecular basis for inherited MHC class II-associated susceptibility to CIA and in turn, for development of novel treatment strategies in this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521085     DOI: 10.1002/(SICI)1521-4141(199802)28:02<755::AID-IMMU755>3.0.CO;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Association of MHC and rheumatoid arthritis. Regulatory role of HLA class II molecules in animal models of RA: studies on transgenic/knockout mice.

Authors:  V Taneja; C S David
Journal:  Arthritis Res       Date:  2000-04-12

2.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice.

Authors:  Alexei von Delwig; Daniel M Altmann; Fraser G Charlton; Norman McKie; John D Isaacs; Rikard Holmdahl; John H Robinson
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

4.  Preserved Proteins from Extinct Bison latifrons Identified by Tandem Mass Spectrometry; Hydroxylysine Glycosides are a Common Feature of Ancient Collagen.

Authors:  Ryan C Hill; Matthew J Wither; Travis Nemkov; Alexander Barrett; Angelo D'Alessandro; Monika Dzieciatkowska; Kirk C Hansen
Journal:  Mol Cell Proteomics       Date:  2015-05-06       Impact factor: 5.911

5.  Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Authors:  Inger Gjertsson; Karen L Laurie; James Devitt; Steven J Howe; Adrian J Thrasher; Rikard Holmdahl; Kenth Gustafsson
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

6.  Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis.

Authors:  Maria Cristina De Rosa; Bruno Giardina; Caterina Bianchi; Cristiana Carelli Alinovi; Davide Pirolli; Gianfranco Ferraccioli; Maria De Santis; Gabriele Di Sante; Francesco Ria
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

7.  MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis.

Authors:  Jianya Huan; Laurie J Kaler; Jeffery L Mooney; Sandhya Subramanian; Corwyn Hopke; Arthur A Vandenbark; Edward F Rosloniec; Gregory G Burrows; Halina Offner
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

8.  Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis.

Authors:  Johan Bäcklund; Stefan Carlsen; Torsten Höger; Björn Holm; Lars Fugger; Jan Kihlberg; Harald Burkhardt; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

9.  Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure?

Authors:  Jessica L Dunne; Lut Overbergh; Anthony W Purcell; Chantal Mathieu
Journal:  Diabetes       Date:  2012-08       Impact factor: 9.461

10.  Design of glycopeptides used to investigate class II MHC binding and T-cell responses associated with autoimmune arthritis.

Authors:  Ida E Andersson; C David Andersson; Tsvetelina Batsalova; Balik Dzhambazov; Rikard Holmdahl; Jan Kihlberg; Anna Linusson
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.